Androgen deprivation in veterans with prostate cancer: Implications for skeletal health

Annals of Pharmacotherapy

Volumn 40, Issue 12, 2006, Pages 2107-2114

  Wilcox, Andrew ^a   Carnes, Molly L ^b,c,d   Moon, Timothy D ^b,c   Tobias, Renee ^d   Baade, Heather ^d   Stamos, Emily ^d   Elliott, Mary E ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Androgen deprivation; Osteoporosis; Prostate cancer

Indexed keywords

ALENDRONIC ACID; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PAMIDRONIC ACID; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; BONE DENSITY; BONE MASS; CANCER HORMONE THERAPY; CANCER PATIENT; COMBINATION CHEMOTHERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; FOREARM FRACTURE; FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; REVIEW; RIB FRACTURE; RISK; SCORING SYSTEM; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; VETERANS;

EID: 33845645082     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H209     Document Type: Review

References (39)

1. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology 2005;19:651-8.
2. Cancer facts & figures 2006. American Cancer Society. www.cancer.org/ docroot/STT/stt_0.asp (accessed 2006 June 27).
3. Moul JW, Fowler JE Jr. Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003. Urology 2003;62(6 suppl 1):20-8.
4. Chodak GW, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Hormone Therapy Study Group. Urology 2002;60:201-8.
5. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360:103-6.
6. Gilbert SM, McKiernan JM. Epidemiology of male osteoporosis and prostate cancer. Curr Opin Urol 2005;15:23-7.
7. Berruti A, Tucci M, Terrone C, et al. Background to and management of treatment-related bone loss in prostate cancer. Drugs Aging 2002;19:899-910.
8. Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 2002;60(suppl):79-85.
9. Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 2003;97(suppl):789-95.
10. Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001;166:1724-8.
11. Saad F, Perrotte P, Benard F, McCormack M, Karakiewicz PI. Bone health in men with prostate cancer: diagnostic and therapeutic considerations. Can J Urol 2005;12(suppl):9-15.
12. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001;58(suppl):101-7.
13. Moyad MA. Preventing male osteoporosis: prevalence, risks, diagnosis and imaging tests. Urol Clin North Am 2004;31:321-30.
14. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005;104:1633-7.
15. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-55.
16. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-12.
17. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892-9.
18. Bae DC, Stein BS. The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol 2004;172(pt 1):2137-44.
19. Bruder JM. Practical guide to the management of osteoporosis in men with prostate cancer receiving androgen-deprivation therapy. Curr Urol Rep 2005;6:157-8.
20. Meyer HE, Tverdal A, Falch JA. Body height, body mass index, and fatal hip fractures: 16 years' follow-up of 674,000 Norwegian women and men. Epidemiology 1995;6:299-305.
21. Fisher LD, Van Belle G. Counting data. In: Fisher LD, Van Belle G, eds. Biostatistics: a methodology for the health sciences. 1st ed. New York: John Wiley & Sons, 1993:176-245.
22. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003;22:142-6.
23. Kiel DP, Zhang Y, Hannan MT, et al. The effect of smoking at different life stages on bone mineral density in elderly men and women. Osteoporos Int 1996;6:240-8.
24. Nguyen TV, Eisman JA. Risk factors for low bone mass in men. In: Orwoll ES, ed. Osteoporosis in men: the effects of gender on skeletal health. 1st ed. San Diego, CA: Academic Press, 1999:335-61.
25. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol 1996;144:255-63.
26. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
27. Pack AM, Morrell MJ. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. CNS Drugs 2001;15:633-42.
28. Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 2005;16:707-11.
29. Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999;54:607-11.
30. Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 2000;86;449-52.
31. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005-7.
32. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005;90:6410-7.
33. Morabito N, Gaudio A, Lasco A, et al. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. J Bone Miner Res 2004;19:1766-70.
34. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002;87:3656-61.
35. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998;83:1561-6.
36. Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham Study. Ann Intern Med 2000;133:951-63.
37. Maxwell C, Viale PH. Cancer treatment-induced bone loss in patients with breast or prostate cancer. Oncol Nurs Forum 2005;32:589-603.
38. Seeman E. Bone size, mass, and volumetric density: the importance of structure in skeletal health. In: Orwoll ES, ed. Osteoporosis in men: the effects of gender on skeletal health. 1st ed. San Diego, CA: Academic Press, 1999:87-109.
39. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64.